Norway Brønnøysund Record
JOHNSON & JOHNSON
Formation Date
Jul 14, 2026
Capital / Financials
Funding not disclosed
Registered Location
Norway
Legal Status
UTLA
Industry Classification
Sector:
Corporate Dossier
No executive personnel or directors publicly listed in this registry extract.
Media Intercepts
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
- Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Semantic Peers & Competitors
ROOT: TECHNOLOGY
These records share industry text with this entity. Text overlap is exploratory and does not establish that the entities are competitors or commercially comparable.
US SEC filing
Saronic Technologies, Inc.
US SEC filing
SharonAI Holdings Inc. (SHAZ, SHAZW)
Global Enterprise
Adobe
Global Enterprise
Strategy
Macro Trend Alignment
This entity operates in an industry sector currently generating significant public search velocity on our Macro Trend Radar.
Academic Technology Advanced Ai Technology Affordable Technology
SaaS Metrics